Precision medicine

ScottCare Signs Distribution Agreement With Ninety One, Expands Partnership

Technology, Biotechnology, Mobile, Wireless, Health, Other Health, Other Technology, Practice Management, Medical Devices, Software, Networks, General Health, Hospitals, Data Management, Cardiology, Science, Rehabilitation, Method, Efficiency, Diagnosis, Cardiology, Hospital, Partnership, Patient, General manager, Machine learning, Cardiovascular disease, Ninety One, Life expectancy, Precision medicine, Software, CEO, RPM, Artificial intelligence, Data science, Health, Medical device
Monday, October 25, 2021 - 3:00pm

Bleron Baraliu, CEO of Ninety One, added, "This partnership combines ScottCare’s depth of experience and know-how with Ninety One's cloud-native, AI-driven innovative technology, and commitment to becoming the gold standard in cardiac RPM. Clients who choose our platform will leapfrog their peers in attaining the highest quality of patient care and unmatched operational efficiency -- reaping the benefits of digital health and Precision Medicine across several dimensions."

Key Points: 
  • ScottCare Cardiovascular Solutions ( www.scottcare.com ) announced that it has signed an agreement with Ninety One Holding, Inc. ( www.91.life ) to become a principal distributor for Ninety One's cloud software platform for cardiac implanted device monitoring, effectively expanding the partnership between the two firms.
  • Currently, ScottCares 24/7 remote cardiac monitoring service, Ambucor, utilizes the Ninety One platform to provide comprehensive, efficient patient data monitoring and management.
  • The expansion of this relationship will now allow ScottCare to offer Ninety Ones cloud platform directly to clinics that choose to monitor and manage patient data with their own staff.
  • ScottCare is committed to providing exceptional sales and service and will work closely with the Ninety One team on additional developments and enhancements to Ninety Ones cardiac monitoring platform.

Pittsburgh Life Sciences Greenhouse Proudly Announces Portfolio Company Cernostics is Being Acquired by Castle Biosciences

PLA, LGD, Research, Technology, Pittsburgh Life Sciences Greenhouse, CPT, Laboratory developed test, Knowledge, LDT, Pathology, HGD, Patient, Gastroenterology, Barrett's esophagus, Machine learning, Esophageal cancer, BE, Achievement, Dysplasia, Economic development, Commonwealth, Precision medicine, IND, Health, Nasdaq, Acquisition, Entrepreneurship, Medical imaging, Management
Monday, October 25, 2021 - 1:29pm

PITTSBURGH, Oct. 25, 2021 /PRNewswire/ -- Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cernostics, Inc., is being acquired by Castle Biosciences (Nasdaq: CSTL).Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.

Key Points: 
  • PITTSBURGH, Oct. 25, 2021 /PRNewswire/ -- Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cernostics, Inc., is being acquired by Castle Biosciences (Nasdaq: CSTL).Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.
  • Under the terms of the definitive agreement, Cernostics will become a wholly owned subsidiary of Castle Biosciences.
  • The Pittsburgh Life Sciences Greenhouse (PLSG) is a comprehensive life sciences economic development organization.
  • We are dedicated to advancing life sciences in western Pennsylvania by building on the region's strengths in research, clinical care and life sciences entrepreneurship.

AC Immune to Present at the Jefferies London Healthcare Conference

AU, Neurodegeneration, NO, CH, Hoffmann-La Roche, NASDAQ, AC, GB, Genentech, Eli Lilly and Company, RU, Conference, Precision medicine, Company, CEO, Janssen Pharmaceuticals, GLOBE, JP, Pharmaceutical industry
Monday, October 25, 2021 - 12:00pm

LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.

Key Points: 
  • LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.
  • The fireside chat will be available on-demand for attendees during the virtual conference beginning on November 18, 2021.
  • A replay of the fireside chat will also be available on the Events Page of AC Immunes website following the conferences conclusion.
  • SupraAntigen is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU.

Biomarkers of Human Longevity Are Essential for Investment De-Risking and Clinical Trial Predictability, Claims New Book by Seasoned Longevity Investor and Deep Knowledge Analytics Founder

Science, Other Science, Books, Research, Entertainment, Knowledge, Engineering, Initial public offering, Industry, General partnership, Government Technology Agency, Amazon, Human, Founder, Policy, Economist, Data science, Risk, Ageing, Conference, Pragmatism, Investment, Clinical trial, Silicon, UK, Reliability, Growth, Multimedia, Forecasting, Precision medicine, Financial technology, Artificial intelligence, Research, Business, Mouse, Entrepreneurship, Society, Cambridge University Press, Biomarker, AI, Risk management, Renewable energy, Medical device, Management
Monday, October 25, 2021 - 9:20am

A new book by prominent Longevity investor and thought-leader Dmitry Kaminskiy (General Partner of Deep Knowledge Group and Founder of Deep Knowledge Analytics) presents both a warning call to Longevity scientists, investors and policy-makers, signalling a widespread risk for the industrys continued growth and stability, and a proposed solution.

Key Points: 
  • A new book by prominent Longevity investor and thought-leader Dmitry Kaminskiy (General Partner of Deep Knowledge Group and Founder of Deep Knowledge Analytics) presents both a warning call to Longevity scientists, investors and policy-makers, signalling a widespread risk for the industrys continued growth and stability, and a proposed solution.
  • View the full release here: https://www.businesswire.com/news/home/20211025005345/en/
    The warning: the legacy frameworks driving strategic decision making by major Longevity industry players are outdated, underestimate the complexity of biological aging and the translational gap from model organisms (e.g.
  • mice) to humans, and are already now causing significant market failures.
  • If this doesnt change, the industry is at risk of declining investor sentiment.

OncXerna Therapeutics Announces New Biomarker Data from Retrospective Analysis of Results from Phase 1b Ovarian Cancer Trial of Navicixizumab Plus Paclitaxel at the ESGO 2021 Congress

Safety, Fallopian tube cancer, Biology, Poster, LinkedIn, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Usha Menon, ESGO, Neoplasm, TME, Data, Twitter, Fast Track, DCR, Patient, Paclitaxel, PROC, European Society of Gynaecological Oncology, HIV disease progression rates, Food, RNA, ORR, Congress, Intelligence, Time, Precision medicine, PFS, Therapy, Classification, GLOBE, Population, RECIST, Tumor microenvironment, Incidence, Toxic epidermal necrolysis, Progression-free survival, Medical imaging, Pharmaceutical industry, Generic drug
Saturday, October 23, 2021 - 2:00pm

WALTHAM, Mass., Oct. 23, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced new biomarker data from a retrospective analysis of results from its Phase 1b clinical trial of navicixizumab in an electronic poster at the European Society of Gynaecological Oncology (ESGO) Congress 2021.

Key Points: 
  • Data presented in the poster are from a retrospective analysis of results from an open-label Phase 1b trial evaluating navicixizumab, a potentially first-in-class anti-DLL4/VEGF bispecific antibody targeting tumor vasculature, in combination with paclitaxel in patients with platinum-resistant ovarian cancer (PROC).
  • I believe the data presented at ESGO demonstrated the potential of navicixizumab together with the Xerna TME Panel to help address this need.
  • We have been searching for a predictive biomarker for anti-angiogenic therapies and the Xerna TME panel results presented at ESGO are very promising.
  • The Phase 1b trial was an open-label, non-randomized, dose-escalation and expansion study of the safety, tolerability, and efficacy of navicixizumab plus paclitaxel in patients with platinum-resistant ovarian cancer.

Theralink® Technologies Announces an Update on its Securities

CUSIP, Laboratory developed test, LDT, Drug development, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, FDA, Financial Industry Regulatory Authority, FINRA, Precision medicine, Forward-looking statement, OTC, Oncology, Risk management
Friday, October 22, 2021 - 10:00pm

DENVER, Oct. 22, 2021 /PRNewswire/ --Theralink Technologies(OTC: OBMP)("Theralink" or the "Company"), a precision medicine molecular profiling company with a novel phosphoprotein-based Laboratory Developed Test (LDT), today announced an update on its securities.

Key Points: 
  • DENVER, Oct. 22, 2021 /PRNewswire/ --Theralink Technologies(OTC: OBMP)("Theralink" or the "Company"), a precision medicine molecular profiling company with a novel phosphoprotein-based Laboratory Developed Test (LDT), today announced an update on its securities.
  • The company has applied to the Financial Industry Regulatory Authority, Inc. ("FINRA")to have its name changed to "Theralink Technologies, Inc.," and ticker symbol changed to "THER".
  • Theralink Technologies is a proteomics-based, molecular profiling and precision medicine company with a CLIA-certified laboratory located in Golden, Colorado.
  • Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by Theralink Technologies with the Securities and Exchange Commission.

QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities

Biotechnology, Genetics, Health, Clinical Trials, EGFR, Breast cancer, PIK3CA, Biotechnology, Diagnosis, Blood, PCR, Budget, Disease, Health Innovation Manchester, Genomics, Colorectal cancer, NGS, BRAF, Patient, Transport, FDA, FGFR, Large-cell lung carcinoma, List of life sciences, Weather, RNA, Molecular diagnostics, U.S. Securities and Exchange Commission, Life, Senior, Annual report, CityLab, Marketing, Protein, Central business district, COVID-19, Growth, Precision medicine, Polymerase chain reaction, Solution, Health, Knowledge, Lists of disasters, Automation, Heart, Squamous cell carcinoma, George C. Marshall European Center for Security Studies, Global Health Innovative Technology Fund, KRAS, DNA, Pharmaceutical industry, Warehouse
Friday, October 22, 2021 - 11:00am

QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchesters CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.

Key Points: 
  • QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchesters CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.
  • The move into the new facility will help us write the next chapter of this success story.
  • Health Innovation Manchester unites the regions spectrum of public, academic and clinical resources.
  • It is meant to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.

Grand finale of 42PLUS1 Pitch Award at the flagship DxPx Conference Europe

Medical Devices, Health, Other Science, Pharmaceutical, Science, Biotechnology, USD, Technology, Industry, Nigeria Pitch Awards, Digital health, Conference, Precision medicine, Marketing, SLS, List of life sciences, Video game, Pharmaceutical industry
Friday, October 22, 2021 - 10:14am

The DxPx Conference is an established Industry & Investor Partnering Conference for executives of the Diagnostics, Digital Health, Precision Medicine and Life Science Tools industry.

Key Points: 
  • The DxPx Conference is an established Industry & Investor Partnering Conference for executives of the Diagnostics, Digital Health, Precision Medicine and Life Science Tools industry.
  • At this years DxPx Conference EU in Dsseldorf, November 16th the winners of the 42PLUS1 Pitch Award for startups will be elected from a renowned jury of industry experts and investors at the grand finale.
  • 42PLUS1s first round was the US Satellite Award on July 27th at the DxPx Conference US, held up virtually where the winner, Alertgy, received a secured spot for the grand finale at the flagship DxPx Conference in Dsseldorf.
  • Were delighted that there has been such great interest in our 42PLUS1 Pitch Award already in the first 4 months after its launch.

DayOne launches new call for Digital Health startups

Digital, Virtual reality, Ecosystem, Innovation, 3D, Microtechnology, Tech, Patient, Interest, Digital health, Precision medicine, CHF, Medtech, Big Pharma, Pain management, Health, Solution, Investor, AI, Pharmaceutical industry
Friday, October 22, 2021 - 9:37am

Startups with a focus on pain therapy can apply to be considered for the DayOne Accelerator by 5 November 2021.

Key Points: 
  • Startups with a focus on pain therapy can apply to be considered for the DayOne Accelerator by 5 November 2021.
  • DayOne is looking for companies with emerging technologies for pain treatment as well as digital healthcare solutions in pain management.
  • The DayOne Accelerator is the healthcare innovation initiative of Basel Area Business & Innovation and is split into three categories: Digital Health, Tech and Innovation Booster.
  • Going forward, DayOne is opening its accelerator to startups operating in practically all areas of digital health.

DayOne launches new call for Digital Health startups

Digital, Virtual reality, Ecosystem, Innovation, 3D, Microtechnology, Tech, Patient, Interest, Digital health, Precision medicine, CHF, Medtech, Big Pharma, Pain management, Health, Solution, Investor, AI, Pharmaceutical industry
Friday, October 22, 2021 - 9:43am

BASEL, Switzerland, Oct. 22, 2021 /PRNewswire/ -- DayOne, the Healthcare Innovation initiative based in Switzerland, announces the extended deadline for the global call for its digital health accelerator to Friday, 5 November 2021.

Key Points: 
  • Startups with a focus on pain therapy can apply to be considered for the DayOne Accelerator by 5 November 2021.
  • DayOne is looking for companies with emerging technologies for pain treatment as well as digital healthcare solutions in pain management.
  • The DayOne Accelerator is the healthcare innovation initiative of Basel Area Business & Innovation and is split into three categories: Digital Health, Tech and Innovation Booster.
  • Going forward, DayOne is opening its accelerator to startups operating in practically all areas of digital health.